Vineet Laboratories Ltd
Incorporated in 2003, Vineet Laboratories Ltd is in designing, developing, manufacturing of API Intermediates and Bulk Drugs
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
| Free Cash Flow |
| CFO/OP |
Ratios
Figures in Rs. Crores
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Insights
In beta| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Debtors Turnover Ratio Ratio ・Standalone data |
|
||||
| Headcount (Total Employees) Number ・Standalone data |
|||||
| Key Product Dispatch Quantity - N-Butyl Lithium (NBL) kgs ・Standalone data |
|||||
| Net Capital Turnover Ratio Ratio ・Standalone data |
|||||
| Total Number of Batches Produced Number ・Standalone data |
|||||
| Total Production Volume (Quantity Dispatched) kgs ・Standalone data |
|||||
Extracted by Screener AI
Documents
Announcements
-
Board Meeting Intimation for To Consider And Approve The Audited Standalone Financial Results Of The Company For The Fourth Quarter And The Financial Year Ended March 31St, 2026.
2d - Board meeting on May 30, 2026 to approve audited standalone financial results for FY2026.
-
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
15 May - Crisil report for Q3 FY26 rights issue proceeds: Rs 1,352.24 lakh utilized, no deviation reported.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
21 Apr - Submitted Regulation 74(5) certificate for Q4 and FY2026; no demat/remat requests received.
- Closure of Trading Window 30 Mar
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
16 Feb - We enclose herewith the copies of Un-audited standalone financial results of the company for the Third quarter and Nine months ended on December 31, 2025 …
Business Overview[1]
The Co. manufactures and distributes pharmaceuticals, bulk drugs, chemicals, and pesticides. The company also conducts R&D across the biotechnology, healthcare, and industrial sectors, specializing in the export and import of various chemical formulations.